CN100594889C - 一种喷昔洛韦冻干粉针剂及其制备方法 - Google Patents
一种喷昔洛韦冻干粉针剂及其制备方法 Download PDFInfo
- Publication number
- CN100594889C CN100594889C CN200710070018A CN200710070018A CN100594889C CN 100594889 C CN100594889 C CN 100594889C CN 200710070018 A CN200710070018 A CN 200710070018A CN 200710070018 A CN200710070018 A CN 200710070018A CN 100594889 C CN100594889 C CN 100594889C
- Authority
- CN
- China
- Prior art keywords
- penciclovir
- excipient
- injectable powder
- solution
- lyophilized injectable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960001179 penciclovir Drugs 0.000 title claims abstract description 60
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 title claims abstract description 58
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000000843 powder Substances 0.000 claims abstract description 28
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 21
- 238000002347 injection Methods 0.000 claims abstract description 14
- 239000007924 injection Substances 0.000 claims abstract description 14
- 238000002360 preparation method Methods 0.000 claims abstract description 10
- 229920002307 Dextran Polymers 0.000 claims abstract description 4
- BRPTUOYNOCSFRJ-FYZOBXCZSA-N sodium (2S)-4-(2-amino-6-oxo-1H-purin-9-yl)-2-(hydroxymethyl)butan-1-olate Chemical class [Na+].Nc1nc(=O)c2ncn(CC[C@H](CO)C[O-])c2[nH]1 BRPTUOYNOCSFRJ-FYZOBXCZSA-N 0.000 claims abstract description 3
- 239000000243 solution Substances 0.000 claims description 29
- 238000005352 clarification Methods 0.000 claims description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 21
- 229910052799 carbon Inorganic materials 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 14
- 238000004108 freeze drying Methods 0.000 claims description 12
- 238000012856 packing Methods 0.000 claims description 10
- 239000008215 water for injection Substances 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- 238000000859 sublimation Methods 0.000 claims description 7
- 230000008022 sublimation Effects 0.000 claims description 7
- 238000010792 warming Methods 0.000 claims description 7
- 238000004821 distillation Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 4
- 238000005516 engineering process Methods 0.000 abstract description 4
- 230000008014 freezing Effects 0.000 abstract description 2
- 238000007710 freezing Methods 0.000 abstract description 2
- 229940109850 royal jelly Drugs 0.000 abstract 2
- 230000002950 deficient Effects 0.000 abstract 1
- 238000005286 illumination Methods 0.000 description 6
- 238000005070 sampling Methods 0.000 description 6
- 230000005496 eutectics Effects 0.000 description 5
- 229930182470 glycoside Natural products 0.000 description 5
- 150000002338 glycosides Chemical class 0.000 description 5
- 239000002932 luster Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 229960004396 famciclovir Drugs 0.000 description 4
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 4
- 241000700584 Simplexvirus Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- KGSIOVLUJYQLKR-UHFFFAOYSA-N [[4-(2-amino-6-oxo-3h-purin-9-yl)-2-(hydroxymethyl)butoxy]-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C=N2 KGSIOVLUJYQLKR-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- -1 penciclovir monophosphate Chemical class 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- YKBGVTZYEHREMT-UHFFFAOYSA-N 2-amino-9-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1C1CC(O)C(CO)O1 YKBGVTZYEHREMT-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000001688 Herpes Genitalis Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000021472 generally recognized as safe Nutrition 0.000 description 1
- 201000004946 genital herpes Diseases 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- RMLUKZWYIKEASN-UHFFFAOYSA-M sodium;2-amino-9-(2-hydroxyethoxymethyl)purin-6-olate Chemical compound [Na+].O=C1[N-]C(N)=NC2=C1N=CN2COCCO RMLUKZWYIKEASN-UHFFFAOYSA-M 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Images
Abstract
Description
天数 | 外观色泽 | 澄清度 | pH值 | 含量(标示量%) | 有关物质(%) |
0 | 白色块状物 | 无色澄清 | 10.91 | 103.3 | 0.27 |
10天4000LX光照 | 白色块状物 | 无色澄清 | 10.85 | 103.7 | 0.36 |
10天高温60℃ | 白色块状物 | 无色澄清 | 10.87 | 103.1 | 0.47 |
天数 | 外观色泽 | 澄清度 | pH值 | 含量(标示量%) | 有关物质(%) |
0 | 白色块状物 | 无色澄清 | 10.95 | 102.8 | 030 |
10天4000LX光照 | 白色块状物 | 无色澄清 | 10.80 | 103.1 | 0.37 |
10天高温60℃ | 白色块状物 | 无色澄清 | 10.85 | 102.6 | 0.46 |
天数 | 外观色泽 | 澄清度 | pH值 | 含量(标示量%) | 有关物质(%) |
0 | 白色块状物 | 无色澄清 | 10.84 | 101.6 | 020 |
10天4000LX光照 | 白色块状物 | 无色澄清 | 10.87 | 101.1 | 0.28 |
10天高温60℃ | 白色块状物 | 无色澄清 | 10.90 | 102.3 | 0.38 |
天数 | 外观色泽 | 澄清度 | pH值 | 含量(标示量%) | 有关物质(%) |
0 | 白色块状物 | 无色澄清 | 10.80 | 102.5 | 0.31 |
10天4000LX光照 | 白色块状物 | 无色澄清 | 10.84 | 102.1 | 0.39 |
10天高温60℃ | 白色块状物 | 无色澄清 | 10.85 | 102.8 | 0.45 |
天数 | 外观色泽 | 澄清度 | pH值 | 含量(标示量%) | 有关物质(%) |
0 | 白色块状物 | 无色澄清 | 10.91 | 103.3 | 0.27 |
10天4000LX光照 | 白色块状物 | 无色澄清 | 10.85 | 103.7 | 0.36 |
10天高温60℃ | 白色块状物 | 无色澄清 | 10.87 | 103.1 | 0.47 |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200710070018A CN100594889C (zh) | 2007-07-13 | 2007-07-13 | 一种喷昔洛韦冻干粉针剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200710070018A CN100594889C (zh) | 2007-07-13 | 2007-07-13 | 一种喷昔洛韦冻干粉针剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101108169A CN101108169A (zh) | 2008-01-23 |
CN100594889C true CN100594889C (zh) | 2010-03-24 |
Family
ID=39040559
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200710070018A Active CN100594889C (zh) | 2007-07-13 | 2007-07-13 | 一种喷昔洛韦冻干粉针剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100594889C (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102210686A (zh) * | 2011-04-07 | 2011-10-12 | 罗诚 | 一种含更昔洛韦化合物的药物组合物及其制备方法 |
-
2007
- 2007-07-13 CN CN200710070018A patent/CN100594889C/zh active Active
Non-Patent Citations (2)
Title |
---|
喷昔洛韦在健康受试者的耐受性. 周颖,孙培红,赵侠等.中国临床药理学杂志,第20卷第5期. 2004 |
喷昔洛韦在健康受试者的耐受性. 周颖,孙培红,赵侠等.中国临床药理学杂志,第20卷第5期. 2004 * |
Also Published As
Publication number | Publication date |
---|---|
CN101108169A (zh) | 2008-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103919726A (zh) | 伐昔洛韦脂质体组合药物及其大工业化生产工艺和用途 | |
CN108938654B (zh) | 一种白头翁皂苷b4的注射用制剂 | |
US11351184B2 (en) | Preparation of Pulsatilla saponin B4 for injection | |
CN100522173C (zh) | 含有培美曲塞的药物组合物 | |
CN101209255B (zh) | 连翘酯苷注射制剂及其制备方法 | |
CN1814166A (zh) | 注射用生脉粉针制剂及其制备方法 | |
CN102614492B (zh) | 一种含有棘白菌素类抗真菌剂米卡芬净的液体药用组合物 | |
CN100594889C (zh) | 一种喷昔洛韦冻干粉针剂及其制备方法 | |
CN101683356A (zh) | 一种注射用水溶性维生素制剂及其制备方法 | |
CN100375622C (zh) | 一种氟尿嘧啶冻干粉针剂及其制备方法 | |
CN101574362A (zh) | N-烷酰基虫草素在制备治疗肿瘤疾病的药物中的应用 | |
CN103054817B (zh) | 一种单磷酸阿糖腺苷的药物组合物及其制备方法 | |
CN100490819C (zh) | 具有不同性状的药物及其制备和用途 | |
CN103877025A (zh) | 一种芬苯达唑可溶性粉及其制备方法 | |
CN103980279B (zh) | 一种甲氨蝶呤化合物及注射用甲氨蝶呤 | |
CN102526714B (zh) | 治疗肿瘤的药物组合物及其制备方法 | |
CN103393688B (zh) | 一种含亚叶酸钙和氟尿嘧啶的药物组合物 | |
CN1285335C (zh) | 一种盐酸吡硫醇冻干粉针剂及其制备方法 | |
US20020051778A1 (en) | Method for treatment of malignant neoplasms and a complex preparation having antimalignant activity | |
CN102895184A (zh) | 盐酸表柔比星注射液 | |
CN107837237B (zh) | 一种培美曲塞二钠药物组合物及其制备方法 | |
CN101780083B (zh) | 一种亚叶酸钙与苯丙氨酸的组合物及其制备方法 | |
CN105232571A (zh) | 一种单磷酸阿糖腺苷药物组合物 | |
CN103083243A (zh) | 一种多拉菌素可溶性粉及其制备方法 | |
CN106963768A (zh) | 一种药物组合物及用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Penciclovir freeze dried and method of manufacturing the same Effective date of registration: 20150128 Granted publication date: 20100324 Pledgee: Bank of Communications Ltd Jinhua branch Pledgor: Zhejiang Jiafeng Pharmaceutical Co., Ltd. Registration number: 2015990000078 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20150626 Granted publication date: 20100324 Pledgee: Bank of Communications Ltd Jinhua branch Pledgor: Zhejiang Jiafeng Pharmaceutical Co., Ltd. Registration number: 2015990000078 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Penciclovir freeze dried and method of manufacturing the same Effective date of registration: 20171207 Granted publication date: 20100324 Pledgee: Bank of Communications Ltd Jinhua branch Pledgor: Zhejiang Jiafeng Pharmaceutical Co., Ltd. Registration number: 2017330000262 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20190118 Granted publication date: 20100324 Pledgee: Bank of Communications Ltd Jinhua branch Pledgor: Zhejiang Jiafeng Pharmaceutical Co., Ltd. Registration number: 2017330000262 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |